Since c-src overexpression increases colonic cell invasiveness and because both Src activity and urokinase receptor protein are elevated in invasive colon cancers, the present study was undertaken: 1) to determine if a constitutively active Src regulates urokinase receptor expression and 2) to identify required cis-elements and trans-acting factors. SW480 colon cancer cells transfected with an expression plasmid (c-srcY527F) encoding a constitutively active Src protein manifested increased urokinase receptor gene expression and Src activity. Treatment of the src transfectants with a Srcinhibitor (PD173955) reduced urokinase receptor protein levels and laminin degradation. Inasmuch as we recently implicated an upstream region of the urokinase receptor promoter (؊152/؊135) in constitutive urokinase receptor expression, we determined its role for the induction by src. Whereas the activity of a CAT reporter driven by this region was stimulated by c-srcY527F, the u-PAR promoter mutated at the Sp1-binding motif in the ؊152/؊135 region was not. Nuclear extracts from the src transfectants demonstrated increased Sp1 binding to region ؊152/؊135 compared with those from SW480 cells. Finally, endogenous urokinase receptor protein amounts in 10 colon cancers and corresponding normal colon correlated with Src specific activity. These data suggest that urokinase receptor gene expression is regulated by Src partly via increased Sp1 binding.
The urokinase receptor (u-PAR), 1 a heavily glycosylated, 45-60-kDa cell surface protein, binds the serine protease urokinase specifically and with high affinity (K D ϳ0.5 nM) (1, 2) . The u-PAR (1) is comprised of three similar repeats approximately 90 residues each (3, 4) with the amino-terminal domain binding the plasminogen activator and the carboxyl-terminal domain tethering the binding protein to the cell surface via a glycosyl phosphatidylinositol anchor (4) .
The u-PAR plays an important role in many physiological and pathological functions including wound healing, tissue remodeling, and tumor cell invasion and metastasis (5) (6) (7) (8) . The ability of the u-PAR to promote these biological effects is a consequence of its diverse function. First, urokinase bound to the u-PAR activates plasminogen much more efficiently than the fluid-phase plasminogen activator (9) , thereby facilitating basement membrane degradation. Second, u-PAR clears urokinase-inhibitor complexes from the extracellular space via an ␣ 2 -macroglobulin receptor-dependent endocytotic mechanism (10, 11) . Third, the u-PAR interacts with the extracellular domain of integrins allowing association with the cytoskeleton, thereby mediating cell adhesion and migration (12) (13) (14) . Fourth, the u-PAR is chemotactic for human monocytes and mast cells, and this may contribute to inflammatory and tissue remodeling processes, which are also often observed in tumor infiltrated areas (6, 15) .
The spread of a cancer to distant sites is characterized by extensive tissue remodeling in which surrounding normal tissue and extracellular matrix are proteolytically degraded. Several lines of evidence have implicated the u-PAR in this process. Thus, the overexpression of a human u-PAR cDNA increases the invasion of human osteosarcoma cells through an extracellular matrix-coated porous filter (16) , whereas downregulating u-PAR levels using either antisense expression constructs, oligonucleotides, or synthetic compounds reduces the ability of divergent invasive cancers to invade in vitro and in vivo (17) (18) (19) . Finally, clinical studies on colon and gastric cancers have revealed a correlation between high u-PAR expression and short survival times (20, 21) .
The level of surface-u-PAR is controlled mainly via the regulation of transcription of the seven-exon u-PAR gene located on chromosome 19q13 (22, 23) , although altered mRNA stability and receptor recycling may represent other means of control (24 -26) . Regarding transcriptional regulation, Soravia et al. (27) reported that the basal expression of the gene was regulated via Sp1-binding motifs located proximal (Ϫ110/Ϫ24) to the transcriptional start site. Our laboratory showed that both the constitutive and phorbol 12-myristate 13-acetate-inducible expression of the gene required a footprinted region (Ϫ190/ Ϫ171) of the promoter containing an AP-1 motif (28) . A second region of the promoter (Ϫ152/Ϫ135) bound with an AP-2␣-related protein was also demonstrated to be required for the constitutive u-PAR gene expression and moreover for u-PAR mediated extracellular matrix degradation (29) .
Since the u-PAR is a key protein in promoting tissue remodeling, it is of essential importance to identify molecules regu-lating its expression. One possible candidate is the c-src gene, which encodes the pp60 c-src protein-tyrosine kinase, since (a) its specific activity is higher in distant metastases as compared with the primary colonic tumors (30) and (b) this proteintyrosine kinase stimulates in vitro invasion of rat colonic cells (31) . Therefore, we conducted the present study with the following objectives: 1) to determine whether a constitutively active Src regulates u-PAR gene expression, and 2) to elucidate the molecular mechanisms by which this occurs. Our data show, for the first time, that the urokinase-receptor gene is transcriptionally regulated by this protein-tyrosine kinase and that this induction requires an upstream sequence (Ϫ152/ Ϫ135) bound with Sp1.
EXPERIMENTAL PROCEDURES
Vectors, Reagents, and Antibodies-The u-PAR CAT reporter consists of 449 base pairs of sequence stretching from Ϫ398 to ϩ51 (relative to the transcription start site) cloned into the XbaI site of the pCATBasic vector (Promega, Madison, WI). The u-PAR-firefly luciferase reporter was generated by cloning the aforementioned sequence into the SmaI site of pGL3 (Promega). The R2 CAT reporter construct, consisting of an oligonucleotide spanning nucleotides Ϫ154/Ϫ128 of the u-PAR promoter, was as described previously (29) . The urokinase CAT reporter included 2345 base pairs of 5Ј-flanking region of the urokinase promoter fused directly to the reporter. The c-srcY527F construct contained the c-src coding sequence (32) harboring a tyrosine to phenylalanine substitution at codon 527 and cloned into the HindIII/BamHI cloning site of pcDNA3. The ␤-actin-renilla-luciferase reporter plasmid was kindly provided by Dr. Menashe Bar-Eli (Department of Cancer Biology, M. D. Anderson Cancer Center, Houston, TX). The v-mos expression construct was as described elsewhere (33) . Antibodies to Sp1, Sp2, Sp3, and Sp4 were purchased from Santa Cruz Biotechnology. Oligonucleotides were supplied by Genosys Biotechnologies, The Woodlands, TX.
Cell Lines and Cell Culture-SW480 colon adenocarcinoma cells were grown in McCoy's 5A medium supplemented with 10% fetal bovine serum. Stable constitutively active Src-expressing SW480 clones were generated by transfecting SW480 cells with c-srcY527F using LipofectAMINE (34) . G418-resistant clones were generated and propagated in the presence of 400 g/ml G418.
Preparation of Nuclear Extracts and EMSA-Nuclear extracts and EMSA were carried out as described elsewhere (28) . EMSA was carried out as described (28, 29) using 10 g of nuclear extract, 0.6 g of poly(dI-dC), and 2 ϫ 10 4 cpm of a [␥-32 P]ATP T4 polynucleotide kinaselabeled oligonucleotide.
Nuclear Run-on Experiments-These were as described by us previously (35) . Nuclei from approximately 6 ϫ 10 7 cells (SW480, 1D8, and 2C8) were isolated and incubated in the presence of [␣-
32 P]UTP in transcription buffer (150 mM KCl, 5 mM MgCl 2 , 1 mM MnCl 2 , 20 mM HEPES, pH 7.9, 10% glycerol, 5 mM dithiothreitol). Nuclei were then treated with DNase I and proteinase K, and the RNA extracted with phenol/chloroform and precipitated. Radioactive RNA (6.6 ϫ 10 7 cpm) was hybridized to nylon-immobilized u-PAR cDNA, glyceraldehyde-3-phosphate dehydrogenase cDNA, and the linearized empty vector for the u-PAR cDNA (pBC12B1) as a control.
CAT Assays-Cells were transfected at 60% confluence using poly-L-ornithine as described previously (36) . CAT assays were performed as described by us previously (28) . Where indicated, transient transfections were performed in the presence of an RSV-driven luciferase expression vector (4 g) for the determination of transfection efficiencies. The amount of acetylated [
14 C]chloramphenicol was determined using a Storm 840 PhosphorImager (Molecular Dynamics, Sunnyvale, CA) using ImageQuant software.
Luciferase Assays-Luciferase assays for determining the effect of c-srcY527F on the ␤-actin promoter were performed using the Dual Luciferase Reporter Assay System by Promega according to the manufacturer's protocol.
Determination of u-PAR Protein Amounts-Western blotting was performed as described previously (29, 37) . Briefly, cells were extracted into a Triton X-100-containing buffer supplemented with protease inhibitors. Insoluble material was removed by centrifugation and the cell extract immunoprecipitated with a polyclonal anti-u-PAR antibody. The immunoprecipitated material was subjected to standard Western blotting and the blot probed with 5 g/ml of an anti-u-PAR monoclonal antibody (3931; American Diagnostica, Greenwich, CT) and an horseradish peroxidase-conjugated goat anti-mouse IgG. Bands were visualized by enhanced chemiluminescence (Amersham Pharmacia Biotech).
For the determination of u-PAR by ELISA, resected tissue was prepared and assayed as described by the manufacturer (American Diagnostica).
Laminin Degradation Assays-These were carried out as described previously (38) . Cells were harvested with 3 mM EDTA/phosphatebuffered saline (PBS), washed twice, and seeded (500,000 cells) on radioactive laminin-coated (2 g/dish) dishes. The cells were allowed to attach overnight. Subsequently, cell surface u-PAR were saturated by incubating the cells at 37°C for 30 min with 5 nM urokinase and unbound plasminogen activator removed by washing. The cells were then replenished with serum-free medium with, or without, 10 g/ml plasminogen (final concentration). After varying times at 37°C, aliquots of the culture medium were withdrawn and counted for radioactivity. Solubilized laminin represents the degraded glycoprotein (38) .
Generation of Å5, a Urokinase Receptor Binding Antagonist-A urokinase receptor binding antagonist (Å5) was developed based on the sequence of amino acids 20 -30 of its ligand (urokinase). This peptide was synthesized and cyclized using a covalent linker, as described previously (39) . Å5 was tested for its ability to inhibit the binding of 125 I-DFP-urokinase to RKO cells. Cells (2 ϫ 10 4 /well) were seeded in a 48-well plate and allowed to attach overnight at 37°C. The cells were chilled to 4°C, washed three times with cold PBS, and Å5 (diluted in PBS/0.1% bovine serum albumin) added to the wells at various concentrations (0.1-1000 nM).
125 I-DFP-urokinase (0.5 nM final concentration) was then added to each well. Unlabeled DFP-urokinase was used as a positive control to calibrate the assay. The plate was incubated for 2 h at 4°C, and the cells washed extensively, after which they were lysed using 1 M NaOH and radioactivity in each lysate counted using a ␥ counter. These experiments indicated the IC 50 of Å5 to be approximately 11 nM.
Immune Complex Kinase Assays for Determination of Src ActivityThese assays were performed as described elsewhere (34) . Briefly, cells were rinsed twice with 4°C phosphate-buffered saline (PBS) and lysed in 250 -500 l of standard radioimmune precipitation buffer, and tumor and mucosal tissues were homogenized in radioimmune precipitation buffer using a Polytron homogenizer (Brinkmann Instruments, Westbury, NY). Lysates were additionally homogenized using an 18-gauge needle and clarified by centrifugation at 10,000 ϫ g. 250 g of protein was reacted with monoclonal antibody 327 (Oncogene Science Inc., Cambridge, MA) for 1 h for immunoprecipitation of Src. Immune complexes were formed using 6 g of rabbit-anti-mouse IgG (Oreganon Teknika, Durham, NC) for 1 h, followed by 50 l of formalin-fixed Pansorbin (Staphylococcus aureus, Cowan strain; Calbiochem, La Jolla, CA) for 30 min. Pellets were washed three times in 0.1% Triton X-100, 150 mM NaCl, and 10 mM sodium phosphate. The kinase reaction was initiated by adding 10 Ci of [␥-32 P]ATP, 10 mM Mg 2ϩ , 10 g of rabbit muscle enolase (Sigma) as an exogenous substrate, and 100 M sodium orthovanadate in 20 mM HEPES. After 10 min, reactions were terminated by adding SDS sample buffer. Products were separated in an 8% polyacrylamide gel and exposed to an x-ray film overnight.
The amount of Src protein was determined by immunoblotting. Aliquots (50 g of protein) of cell lysate were resolved in an 8% SDSpolyacrylamide gels and transferred to a nitrocellulose filter. After blocking, the filter was incubated for 18 h at 4°C with 1 g/lane of mAb 327 (Oncogene Science Inc., Cambridge, MA) and washed subsequently. Then, the filter was incubated with rabbit anti-mouse IgG and reactive bands visualized with chemiluminescence (see "Determination of u-PAR Protein Amounts").
Statistical Analysis-Statistical comparison of ELISA and CAT results was done using a two-sided Student's t test (SPSS for Windows statistical software, release 6.1.3, SPSS Inc., Chicago, IL). The correlation between u-PAR amounts and specific or relative Src activity in tumor and colonic mucosa tissues was determined by linear regression analysis and Pearson's correlation coefficient. Statistical significance was defined at p Ͻ 0.05. (30) and u-PAR mRNA/protein (20, 35) amounts are elevated in invasive colon cancers, we hypothesized that this protein-tyrosine kinase could regulate the expression of this receptor. To test this hypothesis, we first transiently co-transfected SW480 cells with a CAT reporter driven by 398 base pairs of 5Ј-flanking sequence of the u-PAR promoter and increasing amounts of an expression construct encoding a constitutively active Src (c-srcY527F) (Fig. 1A) . A significant induction of promoter activity was observed with 0.1-10 g of c-srcY527F, whereas the empty expression construct (pcDNA3) had minimal effect on reporter activity. To exclude the possibility that the effect of the constitutively active Src on u-PAR promoter activity was due to a general induction of transcriptional activity, we performed a control experiment comparing the effect of c-srcY527F transfection on a luciferase reporter regulated by either the u-PAR or ␤-actin promoter (Fig. 1B) . ␤-Actin is a principal component of microfilaments and abundantly expressed in non-muscle cells. In contrast to a strong dose-dependent induction of u-PAR promoter activity, the activity of the ␤-actin promoter was unchanged by the expression of the c-srcY527F construct. Thus, it is unlikely that the increased u-PAR promoter activity brought about by the src expression construct is due to a general effect on transcription. The dose dependence of the src expression construct on u-PAR promoter activity was more evident using the luciferase reporter compared with the CAT reporter. This is probably a consequence of substrate depletion of the radioactive chloramphenicol in the latter assays.
RESULTS

U-PAR Promoter Activity Is Increased by Transient Transfection of SW480 Cells with an Expression Construct Encoding a Constitutively Active Src Protein-Since both Src activity
To rule out the possibility that the induction of u-PAR expression by the constitutively active Src was due to the introduction of a transforming gene, we performed an experiment in which the u-PAR promoter CAT reporter was co-transfected into SW480 cells with a v-mos expression construct (33) . A CAT reporter driven by the urokinase promoter, which previously has been shown to be activated by this construct, served as a positive control (Fig. 2) . In contrast to the urokinase reporter, which was activated up to 4-fold, no effect of this non-membrane protein kinase on u-PAR promoter activity was observed. Thus, we consider it unlikely that the induction of u-PAR promoter activity in SW480 cells is a mere effect of expressing a transforming gene.
u-PAR Gene Transcription and u-PAR-mediated Extracellular Matrix Degradation Are Up-regulated in SW480 Clones Stably Transfected with a Plasmid Encoding a Constitutively
Active Src-We then asked whether the stable expression of the constitutively active Src induced endogenous u-PAR gene expression. Toward this end, we compared the amount of u-PAR protein in SW480 cells, characterized by its very low Src-activity, with two derived clones (1D8, 2C8) stably expressing an exogenous constitutively active Src (Fig. 3A) . The growth rates of the untransfected and Src-transfected cells were indistinguishable. Analysis of cell extracts by ELISA indicated that the 2C8 clone expressing the highest level of Src activity (Fig. 3A ) had 8-fold more u-PAR protein (32 Ϯ 5 ng of u-PAR protein/mg of cellular protein) compared with the parental SW480 cells (4 Ϯ 1 ng of u-PAR protein/mg of cellular protein) (Fig. 3B) . The 1D8 clone, characterized by its intermediate Src activity, had an intermediate amount of u-PAR protein (10 Ϯ 2 ng of u-PAR protein/mg of cellular protein). The ELISA data measuring u-PAR protein were corroborated by Western blotting (Fig. 3C ) in which the highest and lowest amount of u-PAR protein was evident in the 2C8 clone and the non-transfected SW480 cells, respectively. The diffuse nature of the immunoreactive bands is probably due to the heavily glycosylated state of the u-PAR protein (40) . To determine if the increased u-PAR protein was due to a higher transcription rate, we performed nuclear run-on experiments comparing parental SW480 cells and SW480 cells stably expressing either neo (SW480 neo) or the constitutively active Src (1D8 and 2C8) (Fig. 3D) . Hybridization of radioactive mRNA from isolated nuclei to a nylon filter-immobilized u-PAR cDNA yielded a signal with 2C8 cells, which was dramatically higher than that achieved with SW480 cells transfected with nothing (SW480) or the neo gene (SW480 neo). Thus, u-PAR gene transcription is induced by an activated Src.
One of the functions of u-PAR is to accelerate plasminogendependent proteolysis via receptor-bound urokinase. Accordingly, we used laminin degradation as a biological end point to measure the effect of the src transfection on the display of the urokinase binding site. Toward this end, we performed laminin degradation assays comparing the activity of SW480, 1D8, and 2C8 cells. SW480 and 2C8 cells in serum-free medium (f, OE) demonstrated minimal solubilization of laminin in the absence of the zymogen, plasminogen (Fig. 4) . After addition of plasminogen, SW480 cells showed a moderate degradation of laminin (50,000 cpm/10 6 cells) in the culture supernatant after 240-min incubation (ϫ). However, addition of plasminogen to the src transfectants resulted in a much stronger increase in laminin solubilization indicating plasmin-dependent proteolysis. In this respect, the 2C8 clone, characterized by the highest Src activity, showed the highest amount of solubilized laminin in the supernatant (Ͼ 200,000 cpm/10 6 cells after 240 min; q) with the 1D8 clone being intermediate (130,000 cpm/10 6 cells; Ⅺ). These data suggested that the stable transfection of a low u-PAR-expressing colon cancer cell line with a plasmid encoding a constitutively active Src results in transcriptional activation of the u-PAR gene, the latter in proportion to the amount of Src activity detected in the individual clones. 
A Specific Src Inhibitor Reduces u-PAR Expression and u-PAR-mediated Extracellular Matrix Degradation-
The results presented so far suggested that the expression of the u-PAR gene is transcriptionally induced by expressing a constitutively active Src cDNA in SW480 colon cancer cells. As a corollary to these experiments, we asked whether the inhibition of Src activity in the SW480 cells stably expressing the constitutively active Src would result in a decrease in u-PAR protein amounts, promoter activity, and laminin degradation. 2C8 cells (the SW480 transfected clone showing the highest Src activity) were treated with varying amounts of PD173955 (41), which specifically targets Src family members, and assayed for u-PAR protein by ELISA. Increasing amounts of the PD173955 led to a dose-dependent decrease in the amount of the urokinase receptor (Fig. 5A) . Similarly, an identical concentration range of the Src inhibitor repressed u-PAR promoter activity (Fig.  5B) . We did not observe changes in growth rate or morphological signs of cell toxicity using this concentration range (data not shown). These results were paralleled by a dose-dependent attenuation in endogenous Src activity (Fig. 5C ) but not in Src protein levels (Fig. 5D ) as demonstrated by immunocomplex kinase assay. We also used laminin solubilization as a biological end point for measuring u-PAR display. Treatment of 2C8 cells with concentrations of PD 173955 that inhibited u-PAR protein amounts blocked laminin solubilization. Similarly, a specific u-PAR inhibitor (Å5) effectively countered (Fig. 6 ) laminin degradation brought about by 2C8 cells incubated with plasminogen, indicating that the laminin degradation achieved was indeed due to cell surface u-PAR display. The effect of the PD173955 on laminin degradation was greater than would be expected based on the reduction in u-PAR protein (Fig. 5A) . We can only speculate that this is due to the repression of endogenous urokinase, which is also regulated by v-src (42) . Thus, the reduced synthesis of the protease would be expected to result in fewer u-PAR molecules bound with the endogenous enzyme despite the preincubation of cells with exogenous urokinase (since the half-life of receptor-bound urokinase is shorter than the duration of the laminin degradation assay (140 (Ref. 43 ) and 240 min, respectively). Nevertheless, these data provide further support for the contention that the u-PAR gene expression is regulated by a constitutively active Src.
The Induction of u-PAR Promoter Activity by the Constitutively Active Src Requires an Upstream Region (Ϫ152/Ϫ135)
Bound with Sp1-We next sought to determine which ciselements of the u-PAR promoter and transcription factors were involved in the transcriptional induction of u-PAR gene expression by c-srcY527F. In a recent report (29) , we demonstrated that constitutive u-PAR promoter activity in another cell line (RKO) is, at least in part, due to a DNase I-footprinted region of the promoter spanning Ϫ152/Ϫ135 (relative to the transcription start site). This region of the promoter contained overlapping non-canonical Sp1 and AP-2 motifs (29) . To determine the potential role of this region in mediating the induction of u-PAR expression in response to the constitutively active Src, the following experiments were carried out. SW480 cells were transiently transfected with a CAT reporter driven by either the u-PAR promoter (u-PAR CAT) or a thymidine kinase (tk) minimal promoter flanked by the Ϫ152/ Ϫ135 u-PAR promoter region (R2-CAT) with, or without, the constitutively active src expression plasmid (Fig. 7) . In the absence of the expression construct, the activity of the R2-CAT was lower than that achieved with the u-PAR CAT. This is to be expected, since we have found that transactivation of the u-PAR gene requires multiple cis elements (28). More importantly, the c-srcY527F caused an increased activity of the CAT reporter driven by either the Ϫ152/Ϫ135 region (R2-CAT) or the wild type u-PAR promoter (u-PAR CAT) (Fig. 7) . This increase in activity of the R2-CAT reporter was not due to an activation of the minimal tk-promoter since the expression construct encoding the constitutively active Src did not increase CAT activity in cells co-transfected with the tk-CAT reporter.
Since the promoter region Ϫ152/Ϫ135 contained putative Sp1 and AP-2 binding motifs, we considered the possibility that the corresponding transcription factors were bound. To explore this possibility, we performed EMSA experiments comparing equal protein amounts of nuclear extracts from SW480, SW480 neo, 1D8, and 2C8 cells for transcription factor binding to an oligonucleotide spanning this region of the u-PAR promoter. At least three bands of slower mobility, which could be competed by a 100-fold excess of unlabeled oligonucleotide, were observed with extracts of parental SW480 cells and src-transfected clones (Fig. 8A) . However, 2C8 cells (which contain the highest Src activity) demonstrated an increased intensity (lane 5) of the slowest migrating complex (marked with a bracket) when com- FIG. 4 . Increased laminin degradation by SW480 clones expressing a constitutively active Src. SW480, 1D8, and 2C8 cells plated in serum-free medium on radioactive laminin-coated dishes were subjected to a laminin degradation assay. At the indicated times, aliquots of the culture supernatant was harvested and counted for radioactivity. After 240 min, cells were enumerated. The data are typical of duplicate experiments. ࡗ, serum-free medium, plasminogen treatment; f, SW480 control; OE, 2C8 control; ϫ, SW480, plasminogen treatment; Ⅺ, ID8, plasminogen treatment; q, 2C8, plasminogen treatment. (Fig. 8A) . On the other hand, the intensity of the fastest-migrating band (marked with an *), presumed to be the AP-2␣-related factor (29) , was similar (compare lanes 1, 3, and 5) between the SW480 neo cells and the src-transfected derivatives (1D8 and 2C8). As a control, nuclear extract from 2C8 cells was incubated with the radioactive Ϫ154/Ϫ128 probe and a 100-fold excess of an oligonucleotide (Ϫ394/Ϫ378) corresponding to a sequence of the u-PAR promoter further upstream. This unlabeled competitor had no discernible effect (compare lanes 9 and 11) on the shifted bands (Fig. 8A) .
Supershifting experiments were performed to confirm the identity of the slowest migrating band (Fig. 8B) . In the absence of antibody, the intensity of the slowest migrating band (marked with a bracket) was again substantially higher in nuclear extracts from the src transfectants (1D8 and 2C8) compared with the untransfected SW480 cells (compare lanes  1, 8, and 15) . Addition of an anti-Sp1 antibody (lanes 4, 11, and 18) supershifted this complex (indicated with a line) and at the same time abolished the shifted band (indicated with bracket) (Fig. 8B) , indicating that the DNA-bound complex contains largely Sp1. On the other hand, antibodies to Sp2, Sp3, and Sp4 had no effect in the EMSA.
We next determined the requirement of the Sp1-like binding motif in this region of the u-PAR promoter for the induction by src. Toward this end, the effect of the constitutively active src expression construct on the activity of a CAT reporter driven by either the wild type u-PAR promoter or the promoter in which nucleotide substitutions (29) abolishing the binding of the Sp1-transcription factor was determined. We found in duplicate experiments (Fig. 9 ) that the promoter, that was unable to bind Sp1 in the region spanning Ϫ152/Ϫ135 (u-PARSp1 mt CAT), had almost lost the ability to be induced by the src expression construct. In contrast, the wild type-u-PAR promoter was stimulated up to 6-fold. Similarly, we were unable to detect stimulation of the u-PAR promoter harboring nucleotide substitutions (u-PARAP-2/Sp1 mt CAT), which simultaneously prevented the binding of the AP-2␣-related factor and Sp1. We have been unable at the present time to generate a mutation that destroys the binding of the AP-2␣-related factor but preserves Sp1 binding, this presumably reflecting the fact that these motifs are overlapping (29) . Nevertheless, taken together, these experiments suggest that a region of the u-PAR promoter spanning Ϫ152/Ϫ135 and bound with Sp1 is required (E) nM amounts of PD173955; or specific u-PAR inhibitor Å5 at 50 (ϫ) and 100 (q) nM were subjected to a laminin degradation assay in the presence of plasminogen and as described for Fig. 4 . The data are representative of two different experiments.
and sufficient for the induction of the gene by the constitutively active src.
The Amount of u-PAR Protein Correlates with Src Activity in Resected Colon
Cancer-Since our data were generated using a cultured colon cancer cell line, it was possible that the increased u-PAR expression brought about by src was unique to a tissue culture environment. To address this possible criticism, we analyzed homogenates of human colon carcinomas, each of them paired with its corresponding adjacent non-malignant tissue, for endogenous Src specific activity (ratio of Src autophosphorylation/Src protein level) and the amounts of endogenous u-PAR protein. A representative autoradiograph of Src kinase activity and corresponding u-PAR protein amounts is shown in Fig. 10A . For patients 1, 5, 6, and 10 ( Fig. 10A) , both Src activity and u-PAR protein were higher in the resected tumors compared with the normal adjacent tissue (Fig. 10A) . In contrast, in patients 7 and 8, Src activity and u-PAR protein amounts were low in both the tumor and the normal tissue. There was a significant correlation between the amounts of endogenous u-PAR protein and Src specific activity when analyzing both tumor and normal tissue (correlation coefficient 0.8258, p Ͻ 0.001) by linear regression, Fig. 10B ). These data indicate that src-dependent induction of u-PAR gene expression in cultured colon cancer cell lines is a reproducible observation in resected colon cancer.
DISCUSSION
The u-PAR plays a critical role in cellular invasion in normal tissues undergoing remodeling and in malignancy for infiltrative cancer. In the present study, we have made a novel finding that a constitutively active Src transcriptionally induces the expression of the u-PAR. Further, we show for the first time that the inductive effect of the constitutively active Src on the expression of a gene is mediated, at least in part, via increased Sp1 binding to the promoter.
Interestingly, in addition to modulating u-PAR expression, this protein-tyrosine kinase up-regulates the production of several proteases. Thus, Sato et al. (44) demonstrated that v-src elevated the expression of the 92-kDa type IV collagenase and in a separate report, Ishidoh et al. (45) found that cathepsin L, was produced in larger amounts in rat fibroblasts transformed with this oncogene. Equally important, v-src also increases the expression of urokinase, which is the ligand for the u-PAR, and this induction requires the catalytic activity of the proteintyrosine kinase and its plasma membrane localization (42, 46) . The observation that src can up-regulate the u-PAR as well as several proteases is of particular interest, since it suggests a coordinate means of regulating a set of genes required for the invasive phenotype.
Considering the evidence presented herein implicating the constitutively active Src in regulating u-PAR expression, how then is this achieved? It was apparent from the current study that Sp1 bound to the u-PAR promoter sequence Ϫ152/Ϫ135 plays a critical role in the src-dependent induction of u-PAR expression. This finding was initially surprising, since this transcription factor is known more for its role in regulating the constitutive expression of housekeeping genes. As mentioned above, v-src up-regulates several genes, including urokinase, the 92-kDa type IV collagenase, cathepsin L, and prostaglandin synthase 2 (42, 44, 45, 47) . However, in those studies, there was little evidence for a role of Sp1 in the regulation of gene expression. Thus, Sato and co-workers (44) reported that the mutation of an Sp1 binding site in the 92-kDa type IV collagenase had little effect on the induction of this metalloproteinase by v-src. Further, while v-src-expressing fibroblasts contained Sp1-like factors bound to the cathepsin L promoter, the amounts complexed were similar using nuclear extracts from the non-transfected counterparts (45) and mutational analysis was not carried out to determine the role of these factors in mediating the inductive effect of the protein-tyrosine kinase. Nevertheless, there are an increasing number of reports in which Sp1 is required for inducible gene expression brought about by other stimuli. For example, platelet thromboxane receptor expression is elevated in response to the phorbol ester phorbol 12-myristate 13-acetate, and this induction has been ascribed to a 14-nucleotide response element bound with Sp1 and located over 1900 base pairs upstream from the transcriptional start site (48) . Likewise, Sp1 cooperates with AP-1 to up-regulate the expression of CD11c expression in myeloid cells (49) and the disruption of two Sp1 binding sites in the promoter of the 12-lipoxygenase gene reduces the epidermal growth factor-induced expression of this gene (50) . Thus, taken together, our data indicate a novel role for Sp1 as a regulator of inducible gene expression in response to src.
Considering the pivotal role of this transcription factor in mediating the inductive effect of Src on u-PAR gene expression, how is the Sp1 altered to effect this stimulation? Our data showed that nuclear extracts from the src-transfected SW480 cells demonstrated increased binding of the Sp1 to region Ϫ152/Ϫ135 of the u-PAR promoter when compared with nuclear extracts from the parental cells. This augmented binding could be a result of increased synthesis of the Sp1 or could reflect a higher DNA binding affinity. While we are unable to distinguish between these two possibilities at the present time, it is worth noting that TGF-␤ stimulates ␣2 (I) collagen expression by increasing the affinity of an Sp1-containing protein complex for its cognate DNA-binding site (51) . On the other hand, to the knowledge of the authors, there are no studies to date showing increased production of the transcription factor brought about by Src.
The finding that region Ϫ152/Ϫ135 of the u-PAR promoter was stimulated by the constitutively active Src in reporter assays is consistent with the notion that this region is sufficient to mediate the inductive effect of the src on u-PAR expression. Indeed, we observed up to an 8-fold induction in activity of a CAT reporter construct regulated by this region compared with an ϳ10-fold elevation in u-PAR transcription as judged by nuclear run-on experiments. Nevertheless, it is still possible that additional cis-elements also contribute to elevated u-PAR expression brought about by src. For example, since it is well established that Src up-regulates the activity and/or binding of AP-1 transcription factors (46, 52, 53) and that the expression of the u-PAR gene is modulated by an AP-1 motif located at Ϫ184 (28), it is very plausible that the inductive effect of Src on u-PAR expression also requires AP-1-binding transactivators. Indeed, we did see an inhibition of src-mediated u-PAR promoter induction when the promoter was mutated at the AP-1 consensus motif described previously (data not shown). Thus, it is more likely that elevated u-PAR expression brought about by the constitutively active Src is the result of the concerted action of multiple transcription factors including Sp1 binding to a region of the promoter spanning Ϫ152/Ϫ135.
We recently demonstrated the requirement of an AP-2␣-related factor bound to the Ϫ152/Ϫ135 region of the u-PAR promoter for the constitutive expression of the binding site in the RKO colon cancer cell line (29) . Although it was apparent from EMSA that this transcription factor was bound to the u-PAR promoter, it does not appear to have a major role in the induction of u-PAR expression by src. Thus, the amount bound in mobility shift assays did not differ between the src transfectants and the untransfected SW480 cells. Further, site-directed mutagenesis of the u-PAR promoter, which maintained the binding of this AP-2␣-related factor but which destroyed Sp1 binding, practically abolished promoter stimulation by src. We can only speculate that the utilization of different transcription factors reflects the different molecular mechanisms by which u-PAR expression is regulated in the constitutive setting and in response to src expression. Alternatively, it may be that this difference is a consequence of the separate cell lines used in the two studies.
Interestingly, while we provide strong evidence for a role of a constitutively active src in the regulation of u-PAR expression, there is ample evidence for a reciprocal interaction at the protein level. Thus, in the fibrosarcoma cell line HT 1080, Src family members co-immunoprecipitate with u-PAR, and one of these, hck, is activated by receptor-bound urokinase (54) . Association of Src family members and tyrosine phosphorylation after urokinase stimulation was also reported for monocytes (55) . In bovine endothelial cells, it has been demonstrated that focal adhesion kinase is tyrosine-phosphorylated upon urokinase stimulation of u-PAR localized at focal cell contacts, the former of which is an effector of Src kinases. All of these findings suggest that Src family members play an important role in u-PAR signaling. Our findings now indicate, that in addition to Src being a downstream target of u-PAR, there is a reciprocal relationship in which the latter is regulated by the former.
In conclusion, we have shown that a constitutively active Src induces the expression of the u-PAR gene. Equally important, we have also demonstrated the involvement of the Sp1 transcription factor in the regulation of src-dependent gene expression. Since other invasion-promoting genes, including cathepsin L, type IV collagenase, and urokinase, are also regulated by src, our results raise the exciting possibility that antagonizing this non-receptor protein-tyrosine kinase could coordinately repress their expression resulting in a suppression of the metastatic phenotype.
